Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort

Abstract

Background: GOLD recommends triple therapy only in COPD patients with frequent exacerbations despite long-acting bronchodilators who exhibit a high blood eosinophil level (≥300/μL). Indication for ICS containing therapy should be reassessed regularly. Methods: The German real life study DACCORD included COPD patients who had received free triple therapy for ≥ 6 months prior to study entry. At baseline, patients were switched to LABA+LAMA fixed-dose combination (FDC) or maintained triple therapy upon discretion of the treating physician. Here, we compare baseline data of the 2 groups. Results: 1182 patients were recruited into DACCORD of which 30.7% were moved to LABA+LAMA FDC. Patients in the LABA+LAMA arm had a more recent primary COPD diagnosis (6.8 vs 8.1 years, p Conclusion: DACCORD is the first prospective real-world study to provide evidence comparing continuation or de-escalation from triple therapy in daily practice. Physicians seemed to follow patient’s or own preference for therapy with dual bronchodilators in patients with milder symptoms and less exacerbations.